Disposition, metabolism and mass balance of [(14)C]apremilast following oral administration

1. Apremilast is a novel, orally available small molecule that specifically inhibits PDE4and thus modulates multiple pro- and anti-inflammatory mediators, and is currently under clinical development for the treatment of psoriasis and psoriatic arthritis.The pharmacokinetics and disposition of [(14)C...

Descripción completa

Detalles Bibliográficos
Autores principales: Hoffmann, Matthew, Kumar, Gondi, Schafer, Peter, Cedzik, Dorota, Capone, Lori, Kei-Fong, Lai, Gu, Zheming, Heller, Dennis, Feng, Hao, Surapaneni, Sekhar, Laskin, Oscar, Wu, Anfan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Informa Healthcare 2011
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3231940/
https://www.ncbi.nlm.nih.gov/pubmed/21859393
http://dx.doi.org/10.3109/00498254.2011.604745

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3231940/
https://www.ncbi.nlm.nih.gov/pubmed/21859393
http://dx.doi.org/10.3109/00498254.2011.604745

Ejemplares similares